Literature DB >> 7114081

Cardiac function in Duchenne's muscular dystrophy. Results of 10-year follow-up study and noninvasive tests.

R H Hunsaker, P K Fulkerson, F J Barry, R P Lewis, C V Leier, D V Unverferth.   

Abstract

The purposes of this study were to: (1) evaluate the progression of cardiac involvement in Duchenne's muscular dystrophy using systolic time intervals (PEP/LVET); (2) determine if the degree of cardiac involvement bears a relation to the severity of skeletal muscle disease; and (3) describe the M-mode and two-dimensional echocardiographic findings. In 1970, systolic time intervals were studied in 16 patients. During the 10-year interim, two patients were lost to follow-up study, and five patients died. Nine remaining patients were re-studied in 1980 with M-mode and two-dimensional echocardiography as well as systolic time intervals. The PEP/LVET value of these nine patients increased from 0.37 +/- 0.05 (mean +/- SD) in 1970 to 0.47 +/- 0.07 (p less than 0.005) in 1980. Three patients remained ambulatory, and their PEP/LVET value (0.41 +/- 0.04) was significantly better than that of the nonambulatory patients (0.50 +/- 0.07, p less than 0.05). The M-mode echocardiography percentage diameter change was also worse in the nonambulatory group (21 +/- 4 percent versus 34 +/- 7 percent, p less than 0.02). The five patients who were nonambulatory in 1970 died in the intervening 10 years. This study demonstrated that the heart disease of Duchenne's muscular dystrophy is progressive and that the severity of skeletal muscle disease is probably associated with the degree of cardiac dysfunction.

Entities:  

Mesh:

Year:  1982        PMID: 7114081     DOI: 10.1016/0002-9343(82)90184-x

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  11 in total

1.  Cardiac syntrophin isoforms: species-dependent expression, association with dystrophin complex and subcellular localization.

Authors:  Yuko Iwata; Munekazu Shigekawa; Shigeo Wakabayashi
Journal:  Mol Cell Biochem       Date:  2005-01       Impact factor: 3.396

Review 2.  Duchenne muscular dystrophy: pathogenetic aspects and genetic prevention.

Authors:  H Moser
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

3.  Development of Duchenne-type cardiomyopathy. Morphologic studies in a canine model.

Authors:  B A Valentine; J F Cummings; B J Cooper
Journal:  Am J Pathol       Date:  1989-10       Impact factor: 4.307

Review 4.  Challenges and opportunities in dystrophin-deficient cardiomyopathy gene therapy.

Authors:  Dongsheng Duan
Journal:  Hum Mol Genet       Date:  2006-10-15       Impact factor: 6.150

5.  The heart in muscular dystrophy: an electrocardiographic and ultrasound study of 20 patients.

Authors:  P Berlit; B Stegaru-Hellring
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1991       Impact factor: 5.270

6.  Suitable analyzed signal duration and criteria for abnormal signal-averaged electrocardiogram on frequency-domain analysis in patients with Duchenne's muscular dystrophy.

Authors:  M Kubo; S Matsuoka; Y Kuroda
Journal:  Pediatr Cardiol       Date:  1996 Mar-Apr       Impact factor: 1.655

7.  Cardiomyopathy of Duchenne muscular dystrophy.

Authors:  L D'Orsogna; J P O'Shea; G Miller
Journal:  Pediatr Cardiol       Date:  1988       Impact factor: 1.655

8.  Cardiac expression of a mini-dystrophin that normalizes skeletal muscle force only partially restores heart function in aged Mdx mice.

Authors:  Brian Bostick; Yongping Yue; Chun Long; Nate Marschalk; Deborah M Fine; Jing Chen; Dongsheng Duan
Journal:  Mol Ther       Date:  2008-12-09       Impact factor: 11.454

9.  Stromal cell-derived factors in Duchenne muscular dystrophy.

Authors:  E Abdel-Salam; I Ehsan Abdel-Meguidr; R Shatla; S S Korraa
Journal:  Acta Myol       Date:  2010-12

10.  Assessment of left ventricular regional function in affected and carrier dogs with Duchenne muscular dystrophy using speckle tracking echocardiography.

Authors:  Hiroshi Takano; Yoko Fujii; Naoko Yugeta; Shinichi Takeda; Yoshito Wakao
Journal:  BMC Cardiovasc Disord       Date:  2011-05-25       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.